Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

12

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Histone deacetylase 1

9

Histone deacetylase 2

9

synaptic transmission, GABAergic

9

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

12

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1964

9

1987

3

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Bipolar disorder, manic episodes

9

Epilepsy

9

Migraine

9

Acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle

3

Recurrent or progressive brain tumors

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

12

Preventing

9

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

9

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Burton, B.S.

9

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

13

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

13

FDA UNII

13

PUBCHEM

13

EPA CompTox

12

ECHA (EC/EINECS)

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIEPILEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIEPILEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Fatty acid derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

10

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 13 results

First page disabled
Previous page disabled
1
Next page
Next page

PHENYLACETIC ACID

ER5I1W795A

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle

Recurrent or progressive brain tumors

Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because ...

it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors.

VALPROIC ACID

614OI1Z5WI

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histone deacetylase 2

synaptic transmission, GABAergic

Histone deacetylase 1

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

5,5-DIMETHYLHYDANTOIN

34032MQ9RO

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Benzeneacetic acid, ammonium salt

PX9XBC6PGQ

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle

Recurrent or progressive brain tumors

Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because ...

it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors.

Sodium phenylacetate

48N6U1781G

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle

Recurrent or progressive brain tumors

Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because ...

it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors.

VALPROATE PIVOXIL

9F5A05A29T

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histone deacetylase 2

synaptic transmission, GABAergic

Histone deacetylase 1

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

DIVALPROEX SODIUM

644VL95AO6

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histone deacetylase 2

synaptic transmission, GABAergic

Histone deacetylase 1

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

VALPROATE MAGNESIUM

Q400352CM2

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histone deacetylase 2

synaptic transmission, GABAergic

Histone deacetylase 1

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

VALPROATE BISMUTH

87PTX621FI

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Histone deacetylase 2

synaptic transmission, GABAergic

Histone deacetylase 1

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

1-STEAROYL-2-VALPROYL-SN-GLYCERO-3-PHOSPHOCHOLINE

W8XK4FDP8E

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1964

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Histone deacetylase 2

synaptic transmission, GABAergic

Histone deacetylase 1

Conditions:

Bipolar disorder, manic episodes

Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, fo...

r the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity.

Showing 1 - 10 of 13 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1